Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is caused by a somatic mutation in the PIG-A gene, which encodes for glycosylphosphatidylinositol, a phospholipid membrane that anchors proteins like CD55 and CD59. These proteins are inhibitors of the complement-mediated lysis. PNH is diagnosed by flow cytometry, and treatment with eculizumab improves the life quality of patients with severe clinical compromise. The aim of this work was to evaluate a hemolytic test that allows monitoring the blockade of the alternative complement pathway caused by eculizumab (herein MET test).
Methods: There were analyzed a total of 163 serum samples from nine patients with PNH under treatment with eculizumab and ten healthy volunteers like controls. The patients were evaluated for 6 months. The MET test consisted in incubating red blood cells from patients (RBC ) with either acidified serum from healthy volunteers and from patients with PNH. The results can be (a) Positive, (b) Blockade profile, or (c) Negative.
Results: Seven patients responded favorably to the eculizumab, and the test evidenced the blockade profile. The two remaining patients were nonresponders to the treatment, with a positive MET test. In these patients, the dose was increased. One responded favorably with a blockade profile, and the other continued to be nonresponder.
Conclusions: The MET test proved to be a useful tool to monitor the blockade of complement by eculizumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijlh.13186 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spectrum of Manifest Strabismus in A Tertiary Eye Care Hospital in Calabar, Nigeria: Demographics, Types and Co-morbidities.
West Afr J Med
September 2024
Department of Ophthalmology, University of Calabar, Calabar, Cross River State, Nigeria.
Background: Strabismus is a potential cause of ocular morbidity.
Objective: The aim of this study was to determine the frequency, types of manifest strabismus and co-morbidities among patients attending a referral paediatric ophthalmology and strabismus clinic in Calabar, Nigeria.
Methods: A retrospective review of case-notes of patients attending the paediatric ophthalmology and strabismus clinic from January 1, 2017 to December 31, 2019 was done.
Clinical and imaging characteristics of 135 cases of infectious sacroiliitis: a retrospective cohort study in China.
Clin Rheumatol
January 2025
Department of Rheumatology and Immunology, The First Medical Center, People Liberation Army General Hospital, Beijing, 100853, China.
To study the clinical, imaging, and computed tomography (CT)-guided biopsy pathology of patients with infectious sacroiliitis (ISI). We retrospectively analysed 135 patients diagnosed with ISI between 2008 and 2020, comprehensively evaluating clinical characteristics, laboratory test outcomes, pathological examination results, and magnetic resonance images (MRI). Among the 135 patients with ISI, 90 (66.
View Article and Find Full Text PDFThe Effect of Supplemental Nursing System on Sucking Success, Weight Gain Findings and Bilirubin Level in Newborns: A Randomized Controlled Trial.
Matern Child Health J
January 2025
Faculty of Health Sciences, Department of Midwifery, Ağrı İbrahim Çeçen University, Ağrı, Turkey.
Purpose: The aim of this study is to determine the effect of supplemental nursing system on, sucking success, weight gain findings and bilirubin levels in newborns.
Design And Methods: The study was conducted as a randomized controlled trial. The population of the research consisted of 71 infants who received care and treatment at the Neonatal Intensive Care Clinic of the hospital located in a province in eastern Turkey between February and June 2023.
Pivotal trial characteristics and types of endpoints used to support Food and Drug Administration rare disease drug approvals between 2013 and 2022.
Clin Trials
January 2025
Rare Diseases Team, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Background/aims: Rare disease drug development faces unique challenges, such as genotypic and phenotypic heterogeneity within small patient populations and a lack of established outcome measures for conditions without previously successful drug development programs. These challenges complicate the process of selecting the appropriate trial endpoints and conducting clinical trials in rare diseases. In this descriptive study, we examined novel drug approvals for non-oncologic rare diseases by the U.
View Article and Find Full Text PDFEvaluating Efficacy and Safety of Crisaborole in Managing Childhood Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Br J Hosp Med (Lond)
January 2025
Department of Pediatrics, Taizhou Women and Children's Hospital, Taizhou, Zhejiang, China.
Atopic dermatitis (AD) is a common chronic inflammatory skin disorder globally. Crisaborole, a nonsteroidal topical phosphodiesterase 4 inhibitor (PDE4i), has been utilized in treating AD. Crisaborole regulates the production of inflammatory cytokines, which are usually overactive among AD patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!